Ananth Kadambi

2.6k citations

25 papers · 2.1k indexed · 2 hit papers · h-index 10

Impact in

Oncology top 5%
- Lymphatic System and Diseases
- Cancer Cells and Metastasis
Cancer Research top 5%
- Cancer, Hypoxia, and Metabolism

Papers in

Health Informatics 2
- Artificial Intelligence in Healthcare and Education 2
Family Practice 1

Co-authors: Rakesh K. Jain Dai Fukumura Chae‐Ok Yun Yotaro Izumi Takeshi Gohongi Paul L. Huang Donald G. Buerk Lance L. Munn
Journals: Applied Health Economics and Health Policy (2 papers)Clinical and Translational Science (2 papers)Journal of Clinical Oncology (2 papers)Value in Health (2 papers)Clinical Infectious Diseases (1 paper)
Partner nations: United States United Kingdom Germany

In The Last Decade

Ananth Kadambi

20 papers receiving 2.1k citations

Hit Papers

align trajectories log scale

Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics 2002 · 767 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 Science
2001 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Ananth Kadambi

Since Specialization

Citations

This map shows the geographic impact of Ananth Kadambi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ananth Kadambi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ananth Kadambi more than expected).

Fields of papers citing papers by Ananth Kadambi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ananth Kadambi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ananth Kadambi. The network helps show where Ananth Kadambi may publish in the future.

Co-authors

The 25 scholars most cited alongside Ananth Kadambi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ananth Kadambi Line = papers co-authored together Ananth Kadambi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Potential Meets Practicality: AI's Current Impact on the Evidence Generation and Synthesis Pipeline in Health Economics Clinical and Translational Science ·Nichola R. Naylor, Noemi Hummel, Carl de Moor, Ananth Kadambi	2025	1
2	Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort PubMed ·Giancarlo Pesce, Mit Patel, Gaëlle Gusto, Ananth Kadambi, Aastha Chandak, Terri Madison	2025	0
3	Clinical Outcomes of COPD Patients Hospitalized for SARS-Cov-2 Infection During the Omicron Era: Comparative Effectiveness of Initiating Remdesivir in Addition to Corticosteroids Versus Corticosteroids Alone Viruses ·Neera Ahuja, Heng Jiang, Marc Milano, Roman Casciano, Ananth Kadambi, Tom Oppelt, Fariborz Rezai, Martin Kolditz, Veronika Müller, Essy Mozaffari	2025	0
4	Critical Roles for Modeling and Simulation and Real‐World Evidence to Inform Challenges in Clinical Trial Diversity Planning Clinical and Translational Science ·Ananth Kadambi, Elke H. J. Krekels, Antal Martinecz, Geoff Fatzinger, Hannah M. Jones, Artak Khachatryan, Karen Rowland Yeo, Fran Brown	2025	0
5	EE421 Integrating Payer Reimbursement Strategies Into Modeling and Simulation (M&S)-Based Methods to Redefine Drug Development Value in Health ·Ananth Kadambi, Roman Casciano, C. de Moor, Phil E M Smith	2024	0
6	Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19 Clinical Infectious Diseases ·André C. Kalil, Aastha Chandak, Luke Moore, Neera Ahuja, Martin Kolditz, Roman Casciano, Ananth Kadambi, Mohsen Yaghoubi, Sotirios Tsiodras, Jakob J Malin, Essy Mozaffari, Michele Bartoletti	2024	0
7	Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval Clinical Pharmacology & Therapeutics ·Mohamed Kamal, Samit Ganguly, Ananth Kadambi, Patrick F. Smith	2024	2
8	MSR41 Application of Artificial Intelligence As a Decision Support Tool for Abstract Screening: Implications for Time and Cost Savings Value in Health ·Allie Cichewicz, Ananth Kadambi, Luc Lavoie, Leena Mittal, Vidaurre-Rojas Pierre, R. Raorane	2023	1
9	Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis Dermatology and Therapy ·April W. Armstrong, Richard B. Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniela R. Junqueira, Tracy Westley, Renata M. Kisa, Carolin Daamen, Matthias Augustin	2023	23
10	Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer BMC Cancer ·Qi Zhao, Rachel Hughes, Binod Neupane, Kristin Mickle, Yun Su, Isabelle Chabot, Marissa Betts, Ananth Kadambi	2021	4
11	The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin’s Lymphoma Clinical Therapeutics ·N. Muszbek, Ananth Kadambi, Tereza Lanitis, Anthony J. Hatswell, Dilip Patel, Lixia Wang, Jack W. Singer, Ruth Pettengell	2016	9
12	A Canadian Study of the Cost-Effectiveness of Apixaban Compared With Enoxaparin for Post-Surgical Venous Thromboembolism Prevention Postgraduate Medicine ·Nikhil Revankar, John Patterson, Ananth Kadambi, Vincent Raymond, Wissam El-Hadi BSc	2013	18
13	Inclusion of Compliance and Persistence in Economic Models Applied Health Economics and Health Policy ·Ananth Kadambi, Robert J. Leipold, M. Feldman, Sonja Sorensen, Denis Getsios	2012	8
14	Inclusion of Compliance and Persistence in Economic Models Applied Health Economics and Health Policy ·Ananth Kadambi, Robert J. Leipold, M. Feldman, Sonja Sorensen, Denis Getsios	2012	7
15	Abstract 9560: Clinical Trial Simulations of Dyslipidemic Patients in a Mechanistic Model of Cardiovascular Disease Predict Little Impact on CHD Events by CETP Inhibitors Circulation ·Karim Wahba, Arthur Lo, Ananth Kadambi, Lyn M. Powell	2011	4
16	A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy Blood ·Brian R. Stoll, Cristiano Migliorini, Ananth Kadambi, Lance L. Munn, Rakesh K. Jain	2003	90
17	Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. PubMed ·D.E. Dolmans, Ananth Kadambi, John S. Hill, Christina A Waters, Byron C. Robinson, Jeffrey P Walker, Dai Fukumura, Rakesh K. Jain	2002	128
18	Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics Science ·Timothy P. Padera, Ananth Kadambi, Emmanuelle di Tomaso, Carla Mouta Carreira, Edward B. Brown, Yves Boucher, Noah C. Choi, Douglas J. Mathisen, John Wain, Eugene J. Mark, Lance L. Munn, Rakesh K. Jain Hit paper breakdown →	2002	767
19	Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. PubMed ·Ananth Kadambi, Carla Mouta Carreira, Chae‐Ok Yun, Timothy P. Padera, D.E. Dolmans, Peter Carmeliet, Dai Fukumura, Rakesh K. Jain	2001	78
20	Role of leukocytes and tissue-derived oxidants in short-term skeletal muscle ischemia-reperfusion injury American Journal of Physiology-Heart and Circulatory Physiology ·Ananth Kadambi, Thomas C. Skalak	2000	37

About Ananth Kadambi

Ananth Kadambi is a scholar working on Health Informatics, Family Practice, Cancer Research, Internal Medicine and Economics and Econometrics, having authored 25 papers that have together received 2.1k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Cancer, Hypoxia, and Metabolism (4 papers), Angiogenesis and VEGF in Cancer (4 papers), Pharmaceutical Economics and Policy (3 papers), Nanoplatforms for cancer theranostics (2 papers), Lymphatic System and Diseases (2 papers), Artificial Intelligence in Healthcare and Education (2 papers) and COVID-19 Clinical Research Studies (2 papers). The work is most often cited by research in Oncology (749 citations), Cancer Research (367 citations), Molecular Biology (1.0k citations), Physiology (360 citations) and Biochemistry (71 citations). Ananth Kadambi has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Rakesh K. Jain, Dai Fukumura, Chae‐Ok Yun, Yotaro Izumi, Takeshi Gohongi, Paul L. Huang, Donald G. Buerk, Lance L. Munn, Carla Mouta Carreira and Timothy P. Padera. Their work appears in journals such as Applied Health Economics and Health Policy, Clinical and Translational Science, Journal of Clinical Oncology, Value in Health and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact